BRPI0515577A - compostos de carbonila que podem ser empregados como inibidores de fator xa de coagulação - Google Patents

compostos de carbonila que podem ser empregados como inibidores de fator xa de coagulação

Info

Publication number
BRPI0515577A
BRPI0515577A BRPI0515577-0A BRPI0515577A BRPI0515577A BR PI0515577 A BRPI0515577 A BR PI0515577A BR PI0515577 A BRPI0515577 A BR PI0515577A BR PI0515577 A BRPI0515577 A BR PI0515577A
Authority
BR
Brazil
Prior art keywords
inhibitors
coagulation factor
employed
carbonyl compounds
compounds
Prior art date
Application number
BRPI0515577-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Bertram Cezanne
Dieter Dorsch
Werner Mederski
Christos Tsaklakidis
Johannes Gleitz
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BRPI0515577A publication Critical patent/BRPI0515577A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0515577-0A 2004-09-29 2005-09-01 compostos de carbonila que podem ser empregados como inibidores de fator xa de coagulação BRPI0515577A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004047254A DE102004047254A1 (de) 2004-09-29 2004-09-29 Carbonylverbindungen
PCT/EP2005/009418 WO2006034769A1 (de) 2004-09-29 2005-09-01 Carbonylverbindungen verwendbar als inhibitoren des koagulationsfaktors xa

Publications (1)

Publication Number Publication Date
BRPI0515577A true BRPI0515577A (pt) 2008-07-29

Family

ID=35395743

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515577-0A BRPI0515577A (pt) 2004-09-29 2005-09-01 compostos de carbonila que podem ser empregados como inibidores de fator xa de coagulação

Country Status (13)

Country Link
US (1) US20080081814A1 (enExample)
EP (1) EP1797071A1 (enExample)
JP (1) JP2008514655A (enExample)
KR (1) KR20070057878A (enExample)
CN (1) CN101031561A (enExample)
AU (1) AU2005289164A1 (enExample)
BR (1) BRPI0515577A (enExample)
CA (1) CA2581732A1 (enExample)
DE (1) DE102004047254A1 (enExample)
MX (1) MX2007003470A (enExample)
RU (1) RU2007116036A (enExample)
WO (1) WO2006034769A1 (enExample)
ZA (1) ZA200703443B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
MX2008012945A (es) 2006-04-07 2009-01-15 Vertex Pharma Moduladores de transportadores de cartucho de union a adenosina-trifosfato celular (atp).
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8673920B2 (en) 2009-05-06 2014-03-18 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
MX342288B (es) 2010-04-22 2016-09-23 Vertex Pharma Proceso para producir compuestos de cicloalquilcarboxamido-indol.
EP2632465B1 (en) 2010-10-27 2015-12-30 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9056859B2 (en) 2010-10-29 2015-06-16 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2744499B1 (en) 2011-08-19 2016-09-28 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9527830B2 (en) 2011-09-16 2016-12-27 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013062892A1 (en) 2011-10-25 2013-05-02 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013062900A1 (en) 2011-10-25 2013-05-02 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2773351B1 (en) 2011-10-31 2017-08-23 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2773199B1 (en) 2011-10-31 2019-04-10 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2773206B1 (en) 2011-10-31 2018-02-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2790511B1 (en) 2011-12-16 2016-09-14 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EA025322B1 (ru) 2011-12-22 2016-12-30 Новартис Аг Производные дигидробензооксазина и дигидропиридооксазина
US9012496B2 (en) 2012-07-16 2015-04-21 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof
AR092031A1 (es) 2012-07-26 2015-03-18 Merck Sharp & Dohme Inhibidores del canal de potasio medular externo renal
US9777002B2 (en) 2012-11-29 2017-10-03 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9573961B2 (en) 2012-12-19 2017-02-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2956142B1 (en) 2013-02-18 2017-09-20 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9765074B2 (en) 2013-03-15 2017-09-19 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9751881B2 (en) 2013-07-31 2017-09-05 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
KR102447581B1 (ko) 2014-04-15 2022-09-28 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막전도 조절자 매개 질환 치료용 약제학적 조성물
WO2016127358A1 (en) 2015-02-12 2016-08-18 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
EP3313420B1 (en) 2015-06-25 2024-03-13 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
AU2017235461B2 (en) 2016-03-15 2023-02-23 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
CN106674200B (zh) * 2016-12-21 2019-04-12 西安交通大学 一种含有l-脯氨酰胺片段的化合物及其制备方法和应用
CN108997200A (zh) * 2018-07-17 2018-12-14 成都睿智化学研究有限公司 一种5-氨甲基-哌啶-2-酮的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
DE10329457A1 (de) * 2003-04-03 2005-01-20 Merck Patent Gmbh Ethinylprolinderivate
JP4705015B2 (ja) * 2003-04-03 2011-06-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング カルボニル化合物
DE102004045796A1 (de) * 2004-09-22 2006-03-23 Merck Patent Gmbh Arzneimittel enthaltend Carbonylverbindungen sowie deren Verwendung

Also Published As

Publication number Publication date
DE102004047254A1 (de) 2006-04-13
RU2007116036A (ru) 2008-11-10
WO2006034769A1 (de) 2006-04-06
US20080081814A1 (en) 2008-04-03
CN101031561A (zh) 2007-09-05
KR20070057878A (ko) 2007-06-07
JP2008514655A (ja) 2008-05-08
CA2581732A1 (en) 2006-04-06
ZA200703443B (en) 2008-08-27
MX2007003470A (es) 2007-05-10
EP1797071A1 (de) 2007-06-20
AU2005289164A1 (en) 2006-04-06

Similar Documents

Publication Publication Date Title
BRPI0515577A (pt) compostos de carbonila que podem ser empregados como inibidores de fator xa de coagulação
BRPI0408420A (pt) compostos de carbonila
BRPI0408444A (pt) derivados de 1-n-(fenil)-2-n-(fenil) pirazolidina-1,2-dicarboxamida como inibidores de fator xa de coagulação para o tratamento de trombose
BR0313634A (pt) Derivados de benzimidazol
BRPI0514841A (pt) inibidores de piridila da sinalização de hedgehog, processo de preparação dos mesmos e composição compreendendo os referidos inibidores
MY149143A (en) Thiazole compounds as protien kinase b (pkb) inhibitors
BRPI0411466A (pt) derivados de 1-[(4-etinilfenil)]-2-[(fenil)]-pirrolidina-1,2-dicarboxami da como inibidores de fatores de coagulação xa e viia para o tratamento de trombose
BRPI0515931A (pt) compostos, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades e utilização desses compostos
BRPI0515483A (pt) derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase
ATE526331T1 (de) Pyrrolopyrimidine für pharmazeutische zusammensetzungen
EA200802213A1 (ru) Способы лечения заболеваний крови
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
BRPI0410979A (pt) composto, composição farmacêutica, e, métodos para tratar uma doença em um animal mediada pela catepsina s e para tratar um paciente submetido a uma terapia
BRPI0517435A (pt) triazóis úteis como inibidores de proteìna cinase
BRPI0514133A (pt) compostos de fórmula i, processo para a sua fabricação, composições farmacêuticas, método para o tratamento e/ou profilaxia de doença que são mediadas por inibidores de cetp e uso dos compostos de fórmula i
BRPI0513379A (pt) derivados de sulfonamida
BRPI0514295A (pt) 1, 5-difenilpirazóis
UA85676C2 (en) Carbonyl compounds
ATE538796T1 (de) Piperidin- und pyrrolidin-beta-secretase-hemmer zur behandlung von alzheimer-krankheit
BR0213680A (pt) Derivados de fenoxi-n-'4-(1,1-dioxoisotiazolidin-2-il) fenil-valeramida e outros compostos como inibidores de fator de coagulação xa para o tratamento de doenças tromboembólicas e tumores
BRPI0417153A (pt) derivados de carboxamida
BRPI0406844A (pt) Derivados de carboxamida e seu uso como inibidores do fator xa
BR0211737A (pt) Derivados fenìlicos como inibidores do fator xa
BRPI0509174A (pt) derivados de prolinila para o tratamento de trombose
WO2006108679A3 (en) Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use to combat cancer

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]